Cidofovir

Structural formula
General
Non-proprietary name	Cidofovir
other names	( S ) - [1- (4-Amino-2-oxo-pyrimidin-1-yl) -3-hydroxy-propan-2-yl] oxy-methylphosphonic acid
Molecular formula	C 8 H 14 N 3 O 6 P
External identifiers / databases
CAS number 113852-37-2 149394-66-1 (dihydrate) EC number 638-807-0 ECHA InfoCard 100.166.433 PubChem 60613 ChemSpider 54636 DrugBank DB00369 Wikidata Q423445
Drug information
ATC code	J05 AB12
Drug class	Antivirals
properties
Molar mass	279.19 g · mol -1
Physical state	firmly
Melting point	260 ° C
safety instructions
Please note the exemption from the labeling requirement for drugs, medical devices, cosmetics, food and animal feed GHS labeling of hazardous substances danger H and P phrases H: 301-315 P: 301 + 310
As far as possible and customary, SI units are used. Unless otherwise noted, the data given apply to standard conditions .

Cidofovir is an acyclic nucleotide analog (monophosphate) of deoxycytidine monophosphate and belongs to the group of antivirals . It inhibits the viral DNA polymerase of many DNA viruses. Cidofovir has been approved under the trade name Vistide (manufacturer Gilead Sciences ) for the intravenous treatment of retinitis caused by the cytomegalovirus in AIDS patients. Efficacy in other viral diseases has not been proven.

Cidofovir cream preparations have been used on several occasions on a trial basis to combat HPV infections. However, HP viruses do not have their own DNA polymerase, which is why the exact mechanism of action of cidofovir in HPV infections is currently unclear. In vitro , cidofovir caused apoptosis of HPV-positive keratinocytes . In various studies with a few patients, the local application of a one percent cream or gel to the condylomata acuminata led to a reduction or complete healing in over 50 percent of the treated patients. For therapy-resistant multiple verrucae vulgares or plantar warts , cure rates of 90 to 100 percent have been reported in individual reports and in a small study with one or three percent cidofovir cream. Systemic side effects of cidofovir were not observed, but local irritation was common . Cidofovir could cause acute kidney failure in lung transplant patients .

Vistide is expressly not intended for intraocular injection or topical use. The background for this information were reports of adverse events such as nephrotoxicity , neutropenia and toxic effects on the eye in connection with non-approved forms of application and use in non-approved indications.

In 2014, Gilead Sciences ceased marketing Vistide .

Web links

• Vistide information from the European Medicines Agency (PDF file; 229 kB)
• Chapter 7: Antiretrovirals and Essential Drugs in HIV Book 2011. The book on HIV and AIDS.
• Chapter 6.2: Substance classes, drug overview in HIV-Buch 2011. The book on HIV and AIDS.

Individual evidence

1. ^ The Merck Index . An Encyclopaedia of Chemicals, Drugs and Biologicals . 14th edition, 2006, p. 377, ISBN 978-0-911910-00-1 .
2. ↑ ^{a b} Data sheet cidofovir hydrate from Sigma-Aldrich , accessed on March 23, 2011 ( PDF ).
3. ^ ^{A b} Gilead Sciences and the European Medicines Agency Rote-Hand-Brief zu Vistide (cidofovir) (Gilead Sciences GmbH of January 12, 2011).
4. ↑ Coremans G et al. Topical cidofovir (HPMPC) is an effective adjuvant to surgical treatment of anogenital condylomata acuminata. In: Dis Colon Rectum . 2003 Aug, PMID 12907906 .
5. ↑ Zedtwitz-Liebenstein K et al. Acute renal failure in a lung transplant patient after therapy with cidofovir. In: Transpl Int . 2001 Dec; 14 (6), PMID 11793044 .
6. ↑ Bulletin on Drug Safety, Issue 1; March 2011, p.7 Risks from the off-label use of cidofovir (Vistide).

This article is about a health issue. It is not used for self-diagnosis and does not replace a diagnosis by a doctor. Please note the information on health issues !